Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action

Author(s): Pieter R. Tuinman, Marcus J. Schultz, Nicole P. Juffermans

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 22 , 2012

Become EABM
Become Reviewer
Call for Editor


Transfusion-related acute lung injury (TRALI) is a subcategory of acute lung injury (ALI). As such, there are many similarities between the syndromes, both clinically and pathophysiologically. Pulmonary changes in fibrin turnover have emerged as a hallmark of ALI, thereby initiating studies investigating the potential of therapeutic interventions aimed at ameliorating this so-called pulmonary coagulopathy. Enhanced coagulation and impaired fibrinolysis are probably also important features of TRALI. In particular, platelets play an important role in mediating injury during a TRALI reaction. In this narrative review, the evidence of the role of coagulopathy and platelet activation in TRALI is discussed. Given that host risk factors for acquiring TRALI have been identified and that there is a time frame in which a preventive strategy in patients at risk for TRALI can be executed, preventive strategies are suggested. In this review, we discuss potential preventive anticoagulant interventions.

Keywords: TRALI, platelets, acetylsalicylic acid, coagulation, fibrinolysis, ALI, therapy, fibrin turnover, pulmonary coagulopathy, anticoagulant interventions

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 01 June, 2012
Page: [3267 - 3272]
Pages: 6
DOI: 10.2174/1381612811209023267
Price: $65

Article Metrics

PDF: 18